Send to

Choose Destination
Oper Neurosurg (Hagerstown). 2018 Sep 1;15(3):270-277. doi: 10.1093/ons/opx233.

Preliminary Exploration of the Diagnosis and Treatment of Skull-Based Chondromyxoid Fibromas.

Author information

Department of Neurosurgery, Huashan Hospital, Fudan University, Shanghai, China.
Department of Pathology, Hua-shan Hospital, Fudan University, Shan-ghai, China.



Chondromyxoid fibromas (CMFs) are benign tumors that occur rarely in the skull base.


To conduct a preliminary exploration of the diagnosis and treatment of cranial CMFs.


A retrospective analysis of 19 cases of CMFs in the base of the skull between 2009 and 2014 in our hospital was conducted. The clinical manifestations, imaging characteristics, pathology, treatment strategies, and outcomes were examined.


The study cohort included 7 women (36.8%) and 12 men (63.2%), and symptom duration ranged from 1 mo to 5 yr. Of the 19 intracranial CMF cases examined, 15 (78.9%) conformed with the diagnostic criteria for extracranial CMF. Resection operations yielded subtotal removal of 13 tumors (68.4%) and partial removal of 6 tumors (31.6%). Postoperative pathological analysis demonstrated that the tumors were characterized by spindle-shaped or stellate cells arranged in a myxoid matrix without mitoses or permeation. Follow-up (range 2-7.3 yr; mean, 4.4 ± 1.7 yr) revealed that symptoms improved postoperatively in 15 cases (78.9%), were maintained in 2 cases (10.5%), and worsened in 2 cases (10.5%). Imaging follow-up revealed that residual tumors were stable in 18 cases (94.7%) and enlarged in 1 case (5.3%).


An accurate diagnosis should involve comprehensive consideration of clinical, radiological, and pathological features. The treatment strategy for CMFs consists of maximizing tumor removal while protecting adjacent key structures. Postoperative stereotactic radiotherapy is appropriate for residual tumors.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center